[1] |
中华医学会儿科学分会消化学组, 中华医学会儿科学分会临床营养学组. 儿童炎症性肠病诊断和治疗专家共识[J]. 中华儿科杂志, 2019,57(7):501⁃507. doi: 10.3760/cma.j.issn.0578⁃1310.2019.07.002.
|
[2] |
Conrad MA, Rosh JR. Pediatric inflammatory bowel disease[J]. Pediatr Clin North Am, 2017,64(3):577⁃591. doi: 10.1016/j.pcl.2017.01.005.
|
[3] |
Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents[J]. JAMA Pediatr, 2015,169(11):1053⁃1060. doi: 10.1001/jamapediatrics.2015.1982.
|
[4] |
Hindryckx P, Novak G, Costanzo A, et al. Disease⁃related and drug⁃induced skin manifestations in inflammatory bowel disease[J]. Expert Rev Gastroenterol Hepatol, 2017,11(3):203⁃214. doi: 10.1080/17474124.2017.1283985.
|
[5] |
中华医学会消化病学分会炎症性肠病学组病理分组, 叶子茵, 肖书渊, 等. 中国炎症性肠病病理诊断专家指导意见[J]. 中华炎性肠病杂志, 2021,5(1):5⁃20. doi: 10.3760/cma.j.cn101480⁃20200731⁃00086.
|
[6] |
Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010[J]. Inflamm Bowel Dis, 2010,16(1):112⁃124. doi: 10.1002/ibd.21048.
|
[7] |
Weidner J, Kern I, Manuwald U, et al. Study protocol epidemiology of inflammatory bowel disease in childhood and adolescence: a systematic review[J]. BMJ Open, 2020,10(12):e037669. doi: 10.1136/bmjopen⁃2020⁃037669.
|
[8] |
Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric Crohn′s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties[J]. Am J Gastroenterol, 2010,105(9):2085⁃2092. doi: 10.1038/ajg.2010.143.
|
[9] |
Shimizu H, Ebana R, Kudo T, et al. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease[J]. J Gastroenterol, 2022,57(5):344⁃356. doi: 10.1007/s00535⁃022⁃01856⁃w.
|
[10] |
赵莺, 徐锦. 粪便钙卫蛋白在儿童炎症性肠病中的临床意义[J]. 检验医学, 2022,37(5):429⁃432. doi: 10.3969/j.issn.1673⁃8640.2022.05.006.
|
[11] |
笪红婷, 徐元宏. 粪便钙卫蛋白检测在肠易激综合征和炎症性肠病鉴别诊断中的意义分析[J]. 国际检验医学杂志, 2022,43(5):634⁃636. doi: 10.3969/j.issn.1673⁃4130.2022.05.026.
|
[12] |
Garber A, Regueiro M. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, etiopathogenesis, and management[J]. Curr Gastroenterol Rep, 2019,21(7):31. doi: 10.1007/s11894⁃019⁃0698⁃1.
|
[13] |
Rogler G, Singh A, Kavanaugh A, et al. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management[J]. Gastroenterology, 2021,161(4):1118⁃1132. doi: 10.1053/j.gastro. 2021.07.042.
|
[14] |
Iida T, Hida T, Matsuura M, et al. Current clinical issue of skin lesions in patients with inflammatory bowel disease[J]. Clin J Gastroenterol, 2019,12(6):501⁃510. doi: 10.1007/s12328⁃019⁃00958⁃y.
|
[15] |
Diaconescu S, Strat S, Balan GG, et al. Dermatological manifestations in pediatric inflammatory bowel disease[J]. Medicina (Kaunas), 2020,56(9):425. doi: 10.3390/medicina56 090425.
|
[16] |
Ickrath F, Stoevesandt J, Schulmeyer L, et al. Metastatic Crohn′s disease: an underestimated entity[J]. J Dtsch Dermatol Ges, 2021,19(7):973⁃982. doi: 10.1111/ddg.14447.
|
[17] |
Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends[J]. Inflamm Bowel Dis, 2011,17(1):423⁃439. doi: 10.1002/ibd.21349.
|
[18] |
Polcz M, Gu J, Florin T. Pyoderma gangrenosum in inflammatory bowel disease: the experience at Mater Health Services′ Adult Hospital 1998-2009[J]. J Crohns Colitis, 2011,5(2):148⁃151. doi: 10.1016/j.crohns.2010.10.006.
|
[19] |
Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease[J]. Clin Rev Allergy Immunol, 2017,53(3):413⁃427. doi: 10.1007/s12016⁃017⁃8617⁃4.
|
[20] |
Alvarez⁃Payares JC, Ramírez⁃Urrea S, Correa⁃Parra L, et al. Mucocutaneous manifestations of inflammatory bowel disease[J]. Cureus, 2021,13(8):e17191. doi: 10.7759/cureus.17191.
|
[21] |
Suh HY, Lee WJ, Na SY. Dermatologic manifestations in inflammatory bowel disease[J]. Korean J Gastroenterol, 2019,73(5):285⁃293. doi: 10.4166/kjg.2019.73.5.285.
|
[22] |
Antonelli E, Bassotti G, Tramontana M, et al. Dermatological manifestations in inflammatory bowel diseases[J]. J Clin Med, 2021,10(2):364. doi: 10.3390/jcm10020364.
|
[23] |
Peyrin⁃Biroulet L, Van Assche G, Gómez⁃Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2017,15(1):25⁃36.e27. doi: 10. 1016/j.cgh.2016.06.025.
|
[24] |
Palucka AK, Blanck JP, Bennett L, et al. Cross⁃regulation of TNF and IFN⁃alpha in autoimmune diseases[J]. Proc Natl Acad Sci U S A, 2005,102(9):3372⁃3377. doi: 10.1073/pnas.04085 06102.
|
[25] |
Li SJ, Perez⁃Chada LM, Merola JF. TNF inhibitor⁃induced psoriasis: proposed algorithm for treatment and management[J]. J Psoriasis Psoriatic Arthritis, 2019,4(2):70⁃80. doi: 10.1177/2475530318810851.
|
[26] |
Ezzedine K, Visseaux L, Cadiot G, et al. Ustekinumab for skin reactions associated with anti⁃tumor necrosis factor⁃α agents in patients with inflammatory bowel diseases: a single⁃center retrospective study[J]. J Dermatol, 2019,46(4):322⁃327. doi: 10.1111/1346⁃8138.14816.
|
[27] |
Tillack C, Ehmann LM, Friedrich M, et al. Anti⁃TNF antibody⁃induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon⁃γ⁃expressing Th1 cells and IL⁃17A/IL⁃22⁃expressing Th17 cells and respond to anti⁃IL⁃12/IL⁃23 antibody treatment[J]. Gut, 2014,63(4):567⁃577. doi: 10.1136/gutjnl⁃2012⁃302853.
|
[28] |
Ho T, Orenstein LAV, Boos MD, et al. Cutaneous small⁃vessel vasculitis in two children with inflammatory bowel disease: case series and review of the literature[J]. Pediatr Dermatol, 2017, 34(5):e235⁃e240. doi: 10.1111/pde.13218.
|